Tevogen Bio Regains Nasdaq Compliance, Removing Delisting Risk
TVGN is trading near its 52-week low of $4.892 (6.9% above the low).
Summary
Tevogen Bio Holdings Inc. announced it has formally regained compliance with Nasdaq's minimum bid price requirement, removing the risk of delisting. The company had previously received a notification in September 2025 for failing to maintain a $1.00 minimum bid price. This positive development ensures TVGN's continued listing on The Nasdaq Global Market, which is crucial for investor confidence and liquidity, particularly for a small-cap biotech firm. This procedural update follows recent positive news regarding its TVGN 489 program for Long COVID and advancements in its PredicTcell™ Beta AI model, which likely contributed to the stock price recovery above the $1.00 threshold.
At the time of this announcement, TVGN was trading at $5.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.2M. The 52-week trading range was $4.89 to $75.50. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.